-transparent.png){kind=logo}
Inbred mouse strains congenic for rapid and slow N-acetyltransferase (NAT) (A.B6, rapid and B6.A, slow) were used to separate the effect of the NAT polymorphism from the influence of other genetically polymorphic enzymes on DNA adduct formation induced by exposure to arylamine carcinogens. Adduct formation was measured by HPLC analysis of 32P-postlabeled nucleotides from DNA of the urinary bladder and liver. Acetylator phenotype was a significant determinant of DNA damage in females as slow acetylators had higher levels of bladder DNA adducts than rapids. This correlation was the reverse of that seen with liver DNA. Older mice (20-23 weeks) formed much higher bladder DNA adduct levels than young mice (7 week). The increase in bladder adduct formation with age was seen in both sexes of all mouse strains. The older male B6 mice showed a 26-fold increase in bladder adducts and the older females showed no more than a 2-fold increase. In addition, the older male B6 mice produced significant amounts of an unidentified, early eluting adduct peak. Biochemical studies of liver NAT and O-acetyltransferase (OAT) activities showed a direct correlation between the levels of liver 2-aminofluorene (AF) NAT activity and levels of liver DNA-adduct formation, but the role of OAT activity in adduct formation in the mouse remains unclear. These results indicate that the NAT phenotype, age and sex are all important determinants of arylamine-DNA adduct formation in mice.
W W Weber, and
G N Levy, and
K J Martell
April 1999,
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
W W Weber, and
G N Levy, and
K J Martell
January 2004,
Research communications in molecular pathology and pharmacology,
W W Weber, and
G N Levy, and
K J Martell
January 1995,
Chemical research in toxicology,
W W Weber, and
G N Levy, and
K J Martell
June 2003,
Toxicology in vitro : an international journal published in association with BIBRA,
W W Weber, and
G N Levy, and
K J Martell
January 1997,
European journal of drug metabolism and pharmacokinetics,
W W Weber, and
G N Levy, and
K J Martell
January 2003,
In vivo (Athens, Greece),
W W Weber, and
G N Levy, and
K J Martell
January 2002,
Anticancer research,
W W Weber, and
G N Levy, and
K J Martell
January 2001,
Anticancer research,
W W Weber, and
G N Levy, and
K J Martell
January 1992,
Progress in clinical and biological research,
W W Weber, and
G N Levy, and
K J Martell
October 1985,
Environmental health perspectives,
